June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
A prospective randomised controlled clinical trial comparing a combination of repeated intravitreal Ozurdex and macular laser therapy versus macular laser monotherapy in centre-involving diabetic macular edema (OZLASE study).
Author Affiliations & Notes
  • Ling Zhi Heng
    Institute of Ophthalmology, London, United Kingdom
    Moorfields Eye Hospital, London, United Kingdom
  • Sobha Sivaprasad
    Moorfields Eye Hospital, London, United Kingdom
  • Roxanne R Crosby-Nwaobi
    Moorfields Eye Hospital, London, United Kingdom
  • Zubin Saihan
    Moorfields Eye Hospital, London, United Kingdom
  • Michael Kerampelas
    Moorfields Eye Hospital, London, United Kingdom
  • Catey Bunce
    Moorfields Eye Hospital, London, United Kingdom
  • Tunde Peto
    Moorfields Eye Hospital, London, United Kingdom
  • Philip G Hykin
    Moorfields Eye Hospital, London, United Kingdom
  • Footnotes
    Commercial Relationships Ling Zhi Heng, Allergan Pharmaceutical (F); Sobha Sivaprasad, Allergan Pharmaceutical (F), Bayer (F), Novartis (F), Roche (F); Roxanne Crosby-Nwaobi, None; Zubin Saihan, None; Michael Kerampelas, None; Catey Bunce, None; Tunde Peto, None; Philip Hykin, Allergan Pharmaceutical (F), Bayer (F), Novartis (F)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 1746. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ling Zhi Heng, Sobha Sivaprasad, Roxanne R Crosby-Nwaobi, Zubin Saihan, Michael Kerampelas, Catey Bunce, Tunde Peto, Philip G Hykin, ; A prospective randomised controlled clinical trial comparing a combination of repeated intravitreal Ozurdex and macular laser therapy versus macular laser monotherapy in centre-involving diabetic macular edema (OZLASE study).. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):1746.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To evaluate the clinical efficacy and safety of combined repeated Ozurdex and macular laser therapy (MLT) compared to MLT monotherapy in participants with visual impairment due to centre-involving diabetic macular oedema (DMO).<br />

Methods: Eighty participants with best corrected visual acuity (BCVA) between 54 to 78 ETDRS letters due to centre-involving DMO were randomized to combination therapy with Ozurdex and MLT or MLT only. The combination arm received mandated Ozurdex injections at baseline and 16 weeks followed by re-treatment criteria guided PRN therapy at 32 and 48 weeks. Participants randomized to MLT only were treated every 16 weeks if clinically significant macula oedema was present. The pre-specified primary efficacy evaluation was the mean change from baseline in BCVA at week 56 measured as ETDRS letter score in the intent-to-treat (ITT) population of all randomized patients after adjusting for baseline visual acuity<br />

Results: The mean change in BCVA at 56 weeks was -0.3 (SD 11.4) ETDRS letters in the combination arm versus +0.4 (SD 9.6) ETDRS letters in the MLT arm (effect estimate 1.15 (95% CI -3.32, 5.61)). However, at 56 weeks the central subfield thickness decreased by -113um (IQR -218,-64) [combination] vs -17um (-128, 12) [MLT arm] (p<0.001). Elevated IOP requiring topical therapy was observed in 8(20 %) eyes in the combination versus 1(2.5%) in the MLT arm. 33% (9/27) of phakic participants in the combination arm underwent cataract surgery.<br /> <br />

Conclusions: Visual outcome following combination therapy did not differ from MLT alone in centre-involving DMO despite a significant decrease in CST likely due to an entry VA related ceiling effect and cataract development.<br />

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×